Found: 5
Select item for more details and to access through your institution.
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients.
- Published in:
- Journal of the International AIDS Society, 2010, v. 13, p. P7, doi. 10.1186/1758-2652-13-S4-P7
- By:
- Publication type:
- Article
Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276).
- Published in:
- Journal of the International AIDS Society, 2010, v. 13, p. O50, doi. 10.1186/1758-2652-13-S4-O50
- By:
- Publication type:
- Article
SUPPORT: 48-week results of fosamprenavir/ ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients.
- Published in:
- 2010
- By:
- Publication type:
- Abstract
Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276).
- Published in:
- 2010
- By:
- Publication type:
- Abstract
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
- Published in:
- Journal of Viral Hepatitis, 2018, v. 25, n. 6, p. 631, doi. 10.1111/jvh.12853
- By:
- Publication type:
- Article